ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) has indicating the firm will be shifting its R&D pipeline, centering its IL-12 gene therapy program on glioblastoma following …
Griffin analyst Keith Markey sees golden prospects ahead for ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), particularly taking into account the seven clinical trials the firm has …
While Synthetic Biologics Inc (NYSEMKT:SYN) investors are waiting for phase 2 results of the company’s flagship drug SYN-004, Griffin analyst Keith Markey is out with a research note, reiterating a …
Griffin analyst Keith Markey was out pounding the table on ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), reiterating a Buy rating and price target of $21.
Griffin’s healthcare analyst Keith Markey weighed in on ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), after the oncology biotech firm disclosed interim Phase 1 data for IL12 gene therapy product Ad-RTS-hIL12, …
Griffin’s healthcare analyst Keith Markey was out pounding the table on ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), reiterating a Buy rating and price target of $21, …
In a research report issued today, Griffin Securities analyst Keith Markey reiterated a Buy rating on Unilife (NASDAQ:UNIS) with a $13.50 price target, …
